- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06793735
Effectiveness of TeleVR App in Cognitive Decline and MCI Patients (TeleVR24)
Effectiveness of Telerehabilitation Plus Virtual Reality App in Patients With Subjective Cognitive Decline, and Mild Cognitive Impairment
The goal of this clinical trial is to evaluate the effectiveness of a telerehabilitation program combined with a virtual reality (VR) app in improving cognitive performance and social skills in patients with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).
The main questions it aims to answer are:
Can a VR telerehabilitation program improve cognitive functions and social skills in patients with SCD and MCI? Are there measurable changes in brain activity, eye movements, and gait patterns after the intervention? Researchers will compare telerehabilitation with a VR group (Experimental Group - EG) to a traditional paper-based cognitive rehabilitation group (Active Control Group - aCG) to determine which approach is more effective.
Participants will:
Undergo an initial assessment, including neurological exams, neuropsychological tests, brain MRI, EEG, eye movement analysis, and gait evaluation.
Participate in a 6-week intervention program:
EG: Use VR apps on smartphones/tablets at home, guided remotely by a therapist. aCG: Perform traditional cognitive exercises using paper-based tasks. Complete follow-up assessments immediately after the intervention and again after three months.
This study will help determine whether telerehabilitation with VR can provide measurable cognitive and social benefits, contributing to improved care strategies for individuals at risk of dementia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial aims to assess the effectiveness of a telerehabilitation program combined with a virtual reality (VR) app in enhancing cognitive performance and social skills in individuals with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).
Study Rationale SCD and MCI are considered critical stages in identifying individuals at risk for dementia. Both conditions are associated with cognitive and social impairments, as well as neurophysiological changes observable through advanced neuroimaging and EEG markers. While traditional cognitive rehabilitation has shown benefits, emerging evidence suggests that telerehabilitation combined with VR may offer enhanced outcomes through its interactive, engaging, and scalable nature.
Primary Objective Evaluate the potential efficacy of a telerehabilitation plus VR intervention in improving cognitive performance and social cognition skills in patients with SCD and MCI.
Secondary Objectives Assess neurophysiological changes (EEG and MRI biomarkers) following the intervention.
Evaluate gait patterns and eye movement parameters. Investigate the usability and patient compliance of the VR app-based intervention.
Study Design Type: Randomized Clinical Trial (RCT) Duration: 6 weeks intervention, with follow-up assessments at baseline (T0), post-intervention (T1), and 3 months after intervention (T2).
Population: Individuals aged 40-80 with SCD or MCI (AD and PD subtypes).
Intervention Groups:
Experimental Group (EG): Participants will use two non-immersive VR apps ("NeuroNation" and "The Sims Mobile") on smartphones/tablets for cognitive and socio-emotional skill training. Training will occur 3 times per week, 30 minutes per session, guided remotely by therapists.
Active Control Group (aCG): Participants will follow a traditional cognitive rehabilitation program using paper-based exercises targeting cognitive domains.
Assessment Tools:
Neuropsychological Assessment: MMSE, MoCA, FAB, Stroop Test, RAVLT, Trail Making Test (TMT-A/B), and more.
Neurophysiological Assessment: EEG and MRI scans for brain activity and structural analysis.
Gait Analysis: Timed Up and Go (TUG) Test with BTS G-WALK®. Eye Movement Analysis: Using an eye-tracking system for fixation, saccades, antisaccades, and smooth pursuit eye movements.
Usability Assessment: System Usability Scale (SUS).
Expected Outcomes:
Improved cognitive and social cognition performance in the experimental group compared to the control group.
Observable changes in EEG and MRI biomarkers correlating with cognitive improvements.
Enhanced usability and acceptance of VR-based telerehabilitation tools among participants.
Significance of the Study:
This trial seeks to bridge the gap between traditional cognitive rehabilitation and innovative, scalable, and cost-effective digital health interventions. Positive outcomes could establish telerehabilitation with VR as a standard intervention for cognitive and social rehabilitation in at-risk populations.
The study adheres to ethical principles outlined in the Declaration of Helsinki, and informed consent will be obtained from all participants before enrollment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maria Grazia Maggio, PhD, PsyD
- Phone Number: +39 090 62128250
- Email: mariagrazia.maggio@irccsme.it
Study Locations
-
-
Italy
-
Messina, Italy, Italy, 98124
- Recruiting
- IRCCS Centro Neurolesi Bonino Pulejo
-
Contact:
- Maria Grazia Maggio, PhD, PsyD
- Phone Number: +39 09062128250
- Email: mariagrazia.maggio@irccsme.it
-
Contact:
- Rocco Salvatore Calabrò, PhD, MD
- Phone Number: +3909062128152
- Email: roccos.calabro@irccsme.it
-
Principal Investigator:
- Maria Grazia Maggio, PhD, PsyD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects diagnosed with MCI (AD and PD) according to the criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA, Albert et al., 2011)
- Subjects diagnosed with SCD according to diagnostic criteria proposed in research settings (Molinuevo et al., 2017)
- All enrolled subjects must be aged between 40 and 80 years and have at least 5 years of education
Exclusion Criteria:
- Presence of psychiatric disorders (major depression, psychosis, anxiety disorders)
- Presence of severe dementia
- History of cerebral ischemia
- Contraindications to brain MRI: pregnant women, pacemakers, non-latest-generation metal joint prostheses, electrodes, neurostimulators, or prostheses that may interfere with magnetic fields, unless there is a written statement of suitability from the specialist who performed the intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Tele-VR Group
Participants in this arm will undergo a Telerehabilitation program using Virtual Reality (VR) apps.
This intervention is designed to improve cognitive and social cognition skills through interactive, engaging exercises conducted remotely.
|
Participants assigned to the experimental group will engage in a six-week telerehabilitation program utilizing two non-immersive Virtual Reality (VR) applications, NeuroNation and The Sims Mobile.
These apps are designed to enhance cognitive performance and social cognition skills through interactive and scientifically validated exercises.
NeuroNation focuses on improving memory, attention, reasoning speed, and mental flexibility, while The Sims Mobile engages participants in realistic social scenarios that challenge their empathy, communication, and problem-solving abilities.
The intervention involves three 30-minute sessions per week, which participants will complete remotely using smartphones or tablets.
Therapists will provide weekly virtual check-ins to monitor progress, address questions, and ensure adherence to the protocol.
This program aims to create an engaging and accessible rehabilitation experience while promoting real-life application of cognitive and social skills improv
|
|
Active Comparator: Active Control Group (aCG)
Participants in this arm will receive a traditional cognitive rehabilitation program using paper-based exercises.
The intervention targets the same cognitive and social domains as the experimental group but uses conventional rehabilitation methods.
|
Participants in the control group will follow a traditional rehabilitation protocol that relies on paper-based cognitive exercises.
This program targets cognitive domains such as attention, memory, and executive functions through tasks like puzzles, memory challenges, and problem-solving activities.
The intervention also spans six weeks, with participants completing three 30-minute sessions per week.
During an initial session, participants will receive all necessary materials and instructions for completing the exercises independently at home.
Therapists will provide weekly remote support via phone or video to track progress and address any concerns.
This conventional approach serves as a baseline for comparison with the innovative telerehabilitation method in the experimental group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Performance Improvement
Time Frame: The time frame for assessing cognitive performance improvement is at baseline (T0), immediately post-intervention (T1, after 6 weeks), and at follow-up (T2, 3 months after the intervention).
|
The primary objective is to evaluate the effectiveness of the telerehabilitation program combined with Virtual Reality (VR) in improving global cognitive performance.
This includes assessing domains such as memory, attention, and executive functioning in patients with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).
|
The time frame for assessing cognitive performance improvement is at baseline (T0), immediately post-intervention (T1, after 6 weeks), and at follow-up (T2, 3 months after the intervention).
|
|
Social Cognition Enhancement
Time Frame: Social cognition improvements will be evaluated over the same time frame as cognitive performance: baseline (T0), post-intervention (T1, after 6 weeks), and follow-up (T2, 3 months after the intervention).
|
Another key objective is to examine the impact of the telerehabilitation program on social cognition skills.
This involves measuring improvements in empathy, Theory of Mind, and overall social interaction abilities, which are critical for maintaining functional independence and quality of life.
|
Social cognition improvements will be evaluated over the same time frame as cognitive performance: baseline (T0), post-intervention (T1, after 6 weeks), and follow-up (T2, 3 months after the intervention).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurophysiological Changes
Time Frame: Neurophysiological changes will be assessed at baseline (T0) and immediately post-intervention (T1, after 6 weeks).
|
A secondary objective is to investigate the neurophysiological changes associated with the intervention.
This includes analyzing EEG parameters (such as changes in alpha, theta, and beta rhythms) and MRI biomarkers (like hippocampal connectivity) to understand the underlying mechanisms driving cognitive and social improvements.
|
Neurophysiological changes will be assessed at baseline (T0) and immediately post-intervention (T1, after 6 weeks).
|
|
Gait and Motor Function Improvement
Time Frame: Gait and motor function assessments will occur at baseline (T0) and post-intervention (T1, after 6 weeks).
|
This objective focuses on evaluating changes in motor function and gait performance, assessed through the Timed Up and Go (TUG) test.
The aim is to explore potential links between cognitive rehabilitation and cognitive-motor integration.
|
Gait and motor function assessments will occur at baseline (T0) and post-intervention (T1, after 6 weeks).
|
Collaborators and Investigators
Investigators
- Study Director: Rosso Salvatore Calabrò, MD,PhD, IRCCS Centro Neurolesi Bonino Pulejo
Publications and helpful links
General Publications
- Barnes DE, Yaffe K, Belfor N, Jagust WJ, DeCarli C, Reed BR, Kramer JH. Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial. Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):205-10. doi: 10.1097/WAD.0b013e31819c6137.
- Isernia S, Di Tella S, Pagliari C, Jonsdottir J, Castiglioni C, Gindri P, Salza M, Gramigna C, Palumbo G, Molteni F, Baglio F. Effects of an Innovative Telerehabilitation Intervention for People With Parkinson's Disease on Quality of Life, Motor, and Non-motor Abilities. Front Neurol. 2020 Aug 13;11:846. doi: 10.3389/fneur.2020.00846. eCollection 2020.
- Amjad I, Toor H, Niazi IK, Pervaiz S, Jochumsen M, Shafique M, Haavik H, Ahmed T. Xbox 360 Kinect Cognitive Games Improve Slowness, Complexity of EEG, and Cognitive Functions in Subjects with Mild Cognitive Impairment: A Randomized Control Trial. Games Health J. 2019 Apr;8(2):144-152. doi: 10.1089/g4h.2018.0029. Epub 2018 Sep 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Synucleinopathies
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- Movement Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Cognitive Dysfunction
- Alzheimer Disease
- Parkinson Disease
- Health Services Administration
- Delivery of Health Care
- Therapeutics
- Patient Care
- Health Services
- Health Care Facilities Workforce and Services
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Telemedicine
- Patient Care Management
- Telerehabilitation
Other Study ID Numbers
- TeleVR App_24
- Current Research Funds 2024 (Other Grant/Funding Number: Ministry of Health, Italy)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Telerehabilitation with Virtual Reality
-
University of Campania Luigi VanvitelliNot yet recruitingStroke | Rehabilitation | Hemiparesis | Upper Extremity Paresis | Motor Impairment
-
University of Sao PauloActive, not recruiting
-
Istanbul UniversityCompletedCarpal Tunnel Syndrome | Peripheral Neuropathy | Median Nerve EntrapmentTurkey
-
Hospital Universitari Vall d'Hebron Research InstituteNora Therapeutics, Inc.; MuvityNot yet recruiting
-
Tzu Chi UniversityCompleted
-
Tan Tock Seng HospitalCompleted
-
Istituto Auxologico ItalianoCompletedGeneralized Anxiety DisorderItaly
-
Riphah International UniversityCompleted
-
Vimonwan HiengkaewUnknownStroke | Movement, Abnormal
-
Kırıkkale UniversityCompletedAlzheimer's DementiaTurkey